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CORRESPONDENCETwo-year Clinical Outcomes of Stent Fractures Following
Primary Femoropopliteal Stenting
In their article ‘Incidence and the Clinical Impact of Stent
Fractures after Primary Stenting for TASC C and D Femo-
ropopliteal Lesions at 1 Year’,1 Davaine et al. explored the
outcomes of patients following infra-inguinal stent fracture.
They reported a 17.8% rate of stent fracture, but a
remarkably low restenosis rate and negligible clinical impact
at 1 year.1
These ﬁndings are at odds with our own experience. Our
recently audited unpublished outcomes of primary femo-
ropopliteal stenting over a 7-year period (441 stents in 263
limbs) demonstrate a stent fracture rate of 6.8% (30/441)
with 66.7% and 88.9% restenosis at 1 and 2 years respec-
tively. In all cases of restenosis, patients reported clinical
symptoms of recurrent claudication or rest pain.
Femoropopliteal stent surveillance, as with infra-inguinal
bypass graft surveillance, appears intuitive to maximise our
patients’ outcomes. However, both surveillance pro-
grammes are expensive, labour intensive, and are per-
formed without any evidence base.2 Daviane et al.1 propose
that although they feel these stent fractures are benign, a
larger study should be performed to guide future therapy
for these complications. Before we embark on such a study,
perhaps it would be more valuable to look at the overall
longer-term outcomes of femoropopliteal stenting beyond
the traditional 1- and 2-year follow-up periods, and the
surveillance regimens employed. We believe this would
elucidate both the clinical value and economic beneﬁt of
surveying femoropopliteal stents. It would also support or
refute this paper’s conclusions that femoropopliteal stent
fracture has low clinical impact.
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Herein, Albayati et al. addressed several comments regarding
our paper “Incidence and the clinical impact of stent fractures
after primary stenting for TASC C and D femoropopliteal
lesions at 1 year”.1 In their own experience they found a lower
fracture rate (6.8% vs. 17.8%) and a higher in-stent restenosis
(ISR) rate associated with stent fracture (66.7% vs. 40%) with
consecutive symptoms in all cases.
Our analysis was on long lesions (220  160 mm).
Different studies have shown that the length of the stented
segment and involvement of distal SFA and the popliteal
artery were determinant factors governing higher stent
fracture rates.2 Moreover, long femoropopliteal occlusions
were treated by the subintimal recanalization technique.
The looped guidewire tip crosses the lesion in the sub-
intimal space, hence splitting apart the media and signiﬁ-
cantly reducing the pool of smooth muscle cells available
around the stent to induce intimal hyperplasia. In 2007, Ko
et al.3 reported better patency for revascularization of long
femoropopliteal occlusions using the subintimal technique
rather than the intraluminal technique. If Albayati et al. had
narrowed their analysis to the most severe (TASC C and D)
lesions with popliteal stenting, they would have probably
observed results less discordant to ours. Furthermore, if not
sought prospectively and systematically, fractures, and in
particular minor fractures, are very often ignored and stent
fracture rate underestimated.
Before correlating stent fracture to symptoms, we ﬁrst
should establish a link, which is not so obvious, between
fractures and ISR or thrombosis. For instance, the correla-
tion between a diffuse ISR and a focal fracture is still difﬁ-
cult to conceive. In contrast, does a focal ISR result from a
stent fracture or from external and internal stresses (calci-
ﬁcation, mechanical stresses, etc.)? Noteworthy, in human
coronary arteries, only stent fractures with separation
impact on the clinical outcome.4 Hence, a larger study with
higher statistical power is indeed required to determine
more precisely where fractures occur and which type of
fracture needs a reintervention.
We agree that long-term follow-up is mandatory. How-
ever, most ISR occur during the ﬁrst 12 months;5 thus, 2
years’ follow-up seems sufﬁcient. Furthermore, the stent is
embedded into the arterial wall and the femoropopliteal
disease is related to de novo lesions rather than restenosis.
The 30 months results of our analysis, which should be
shortly submitted, are in line with this notion.
